China Suzhou-based Acumen BioMedical has completed nearly RMB 100 million ($13.6 million) Series A+ financing led by Qiandao Fund and followed by Broad River Capital, which will be mainly used to expand high-end product lines, raw material and material modification R&D, and global market expansion.
In August 2022, Acumen BioMedical raised nearly RMB100 million in Series A financing from Apricot Capital, Wuxi GuolianXinchuang Private Equity, Broad River Capital and Hoshi Capital.
Founded in November 2020, ATON Bio is a high-tech enterprise mainly focusing on the design, R&D, production and sales of high-end consumables and packages in the fields of life sciences, agriculture, medical diagnostics, and drug discovery, as well as the provision of overall solutions for related consumables and CDMO services.
The Post is Available in: English – 简体中文
English (UK) 
简体中文 
Deutsch 
Français 
Español 
Português 
日本語 
Italiano 
Nederlands 
